A Phase 1 interventional study of GLPG0634 in Renal Impairment, sponsored by Galapagos NV. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-22.
Sponsored by Galapagos NV · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 139 studies in Renal Insufficiency with a site in Germany — 12 open to participants now, 16 under way, 2 of them phase 3. Renal Insufficiency · Germany.
Among the 139 studies in Renal Insufficiency with a site in Germany, this one is the 94th largest by enrollment of the 113 interventional ones that give a count, is one of 7 that started in 2014, is one of 54 in phase 1, and was the 56th registered.
1,413 studies on the registry are indexed under Renal Insufficiency; 145 are open to participants now.
Browse Renal Insufficiency studies →12 of the 139 studies in Renal Insufficiency with a site in Germany are open now. Recruiting first, the newest first:
Debiopharm International SA · Sites in Germany
Ages 18–85
Fresenius Medical Care Deutschland GmbH · Sites in Germany
Takeda · Sites in Germany, Belgium, Estonia and 4 more countries
Ages 18+
Fresenius Medical Care Deutschland GmbH · Sites in Germany, Czechia
Ages up to 18
German Heart Institute · Sites in Germany
Ages 40–69
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 91 Renal Insufficiency studies recruiting now, 48 (53%) set no upper age limit and 18 (20%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
139 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 55 · Phase 2 11 · Phase 3 23 · Phase 4 10
First in 1994; this study’s year is marked. 7 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 40 across 1,060 interventional studies indexed under Renal Insufficiency.
Median enrollment 42 across the 113 interventional studies, 428 across the 25 observational. Of the 112 that completed or were terminated, 34 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 139 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galapagos NV, one of the names counted as Lakefront Biotherapeutics NV. Under that name alone:
Galapagos NV is the lead sponsor of 103 studies on the registry; none are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 11 (79%) have results posted.
Lakefront Biotherapeutics NV has 1 study filed under Renal Insufficiency — fewer than ten, so there is no comparison to draw.
5 of the studies in Renal Insufficiency with a site in Germany that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05374291Phase 3University Medical Center GroningenThe RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD | 2027-07 |
| NCT07185100German Heart InstituteDetermination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR | 2026-12-31 |
| NCT06243731TakedaA Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus (CMV) Infection After Transplantation | 2027-01-31 |
| NCT06054035University Hospital TuebingenSGLT2 Inhibition in Addition to Lifestyle Intervention and Risk for Complications in Subtypes of Patients With Prediabetes | 2027-06-30 |
| NCT07679568Fresenius Medical Care Deutschland GmbHAnalysis of Continuous Kidney Replacement Therapy (CKRT) Treatments With multiFlux Hemofilters Using Regional Citrate Anticoagulation (RCA) or Systemic Heparin Anticoagulation | 2027-10 |
Add all 5 to your calendar (.ics) → With an account.
Among the 139 studies in Renal Insufficiency with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This will be an open label study to assess the influence of renal impairment on the pharmacokinetics (PK) of GLPG0634 and its metabolite after once daily oral administrations of 100 mg GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls.
Also, safety and tolerability of once daily oral doses of GLPG0634 for 10 days in subjects with renal impairment and matched healthy controls will be evaluated.
The study will be divided in two parts.
In Part 1, 3 subjects with severe renal impairment or end-stage renal disease (ESRD) not yet requiring dialysis (Group 1) will be recruited first. Thereafter, 3 subjects with normal renal function (Group 2) will be recruited. If a substantial effect on the PK in renal impaired subjects is observed on Day 10, the sponsor may elect to stop Part 1 of the study without enrolling the complete set of subjects and Part 2 will be initiated. In case no substantial effect on the PK is observed, 3 further subjects in both Group 1 and 2 will be recruited and analysed. If a substantial effect on the PK is observed, the study will proceed to Part 2. Part 2 of the study will not be conducted, if in Part 1 no substantial difference in PK is seen.
In Part 2, Group 3 (mild renal impairment) and Group 4 (moderate renal impairment) will be recruited first. After completion of the mild and moderate impairment groups, Group 5 (normal renal function) will be recruited.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1 - Group 1: subjects with severe renal impairment or end-stage renal disease (ESRD), not on dialysis: Estimated glomerular filtration rate (eGFR) between 15-29 mL/min/1.73 m2 or \<15 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
Drug: GLPG0634
Part 1 - Group 2: subjects with normal renal function: eGFR ≥90 mL/min/1.73m² will be administered GLPG0634 100 mg once daily for 10 days
Drug: GLPG0634
Part 2 - Group 3: subjects with mild renal impairment: eGFR between 60-89 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
Drug: GLPG0634
Part 2 - Group 4:subjects with moderate renal impairment: eGFR between 30-59 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
Drug: GLPG0634
Part 2 - Group 5: subjects with normal renal function: eGFR ≥90 mL/min/1.73 m² will be administered GLPG0634 100 mg once daily for 10 days
Drug: GLPG0634
100 mg oral tablet, intake once daily for 10 days
Also known as: GLPG0634 tablets
Maximum observed plasma concentration (Cmax)
Cmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Area under the plasma drug concentration-time curve over 24 hours (AUC0-24h)
AUC0-24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Cumulative amount excreted in urine expressed in μg and % of the dose administered (Ae)
Ae of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)
Renal clearance (CLR)
CLR (calculated as Ae/AUC, where Ae and AUC are calculated over the same interval) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between dosing on Day 1 up to 48 h after dosing on Day 10 (Day 12)
Plasma concentration observed at 24 h post-dose (C24h)
C24h of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Average plasma concentration (Cavg)
Cavg (calculated as AUC0-24h/24h) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Time of occurrence of Cmax (tmax)
Tmax of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Area under the plasma drug concentration-time curve from zero to the last sampling time at which concentrations were at or above the limit of quantification (AUC0-z)
AUC0-z of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Area under the plasma drug concentration-time curve, extrapolated to infinity (AUC0-∞)
AUC0-∞ of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Apparent terminal half-life (t1/2,λz)
t1/2,λz (calculated from (ln 2)/λz being the apparent terminal rate constant) of GLPG0634 and its metabolite after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Metabolite over parent ratio of AUC0-24h (R)
R (metabolite over parent ratio of AUC0-24h) after single and multiple dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
Accumulation ratio (Rac)
Rac (calculated as AUC0-24h Day 10/AUC0-24h Day 1) after dosing in subjects with renal impairment versus subjects with normal renal function
Time frame: Between Day 1 at pre-dose up to 168 h after the last dose on Day 10 (Day 17)
The number of subjects with adverse events
To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of adverse events (AEs)
Time frame: From screening up to 10 days after last dose (Day 20)
The number of subjects with abnormal laboratory parameters
To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal laboratory parameters
Time frame: From screening up to 10 days after last dose (Day 20)
The number of subjects with abnormal vital signs
To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal vital signs
Time frame: From screening up to 10 days after last dose (Day 20)
The number of subjects with abnormal electrocardiogram (ECG)
To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal electrocardiogram (ECG)
Time frame: From screening up to 10 days after last dose (Day 20)
The number of subjects with abnormal physical examination
To evaluate the safety and tolerability of GLPG0634 in subjects with renal impairment versus subjects with normal renal function in terms of abnormal physical examination
Time frame: From screening up to 10 days after last dose (Day 20)
The record gives a start of Mar 2014, a primary completion of Jul 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: GLPG0634